Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors
Open Access
- 1 April 2016
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 1927-1943
Abstract
The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with locally advanced disease, which requires site-specific combinations of surgery, radiation, and chemotherapy. Despite aggressive therapy, survival outcomes remain poor, and treatment-related morbidity is not negligible. For patients with recurrent or metastatic disease, therapeutic options are further limited and prognosis is dismal. With this in mind, molecularly targeted therapy provides a promising approach to optimizing treatment efficacy while minimizing associated toxicity. The ErbB family of receptors (ie, epidermal growth factor receptor [EGFR], ErbB2/human epidermal growth factor receptor [HER]-2, ErbB3/HER3, and ErbB4/HER4) is known to contribute to oncogenic processes, such as cellular proliferation and survival. EGFR, specifically, is upregulated in more than 90% of HNSCC, has been implicated in radiation resistance, and correlates with poorer clinical outcomes. The central role of EGFR in the pathogenesis of HNSCC suggests that inhibition of this pathway represents an attractive treatment strategy. As a result, EGFR inhibition has been extensively studied, with the emergence of two classes of drug therapy: monoclonal antibodies and tyrosine kinase inhibitors. While the monoclonal antibody cetuximab is currently the only US Food and Drug Administration–approved EGFR inhibitor for the treatment of HNSCC, numerous investigational drugs are being evaluated in clinical trials. This paper will review the role of the ErbB family in the pathogenesis of HNSCC, as well as the evidence-based data for the use of ErbB family inhibition in clinical practice.Keywords
This publication has 105 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and womenCancer, 2008
- Head and neck cancerThe Lancet, 2008
- Trends in head and neck cancer incidence in relation to smoking prevalenceCancer, 2007
- Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2006
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- State-of-the-art management of locally advanced head and neck cancerBritish Journal of Cancer, 2005
- Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neckCancer, 1996
- Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.Journal of Clinical Oncology, 1993
- SMOKING AND DRINKING IN RELATION TO ORAL AND PHARYNGEAL CANCER1988